Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

Treatment follows the whole pattern

Chapter 08 · Patients & families

Treatment follows the whole pattern

There is no single medication ladder for the entire SpA family. Treatment has to fit the active areas of disease, associated conditions and the person’s priorities.

Olga Goodman, MD · Evidence checked: 25 September 2026

Shared goals, individual choices

The aims include controlling inflammation, preserving movement and function, and supporting daily life. Education, a sustainable activity plan and rehabilitation belong alongside medicines. Progress should be judged against agreed goals, with attention to symptoms, examination and relevant tests.

Why the location matters

Non-steroidal anti-inflammatory drugs may relieve symptoms when suitable, but kidney, stomach, cardiovascular and bowel risks matter. Conventional disease-modifying drugs such as methotrexate or sulfasalazine can have a role in peripheral arthritis. They are not established treatment for purely axial inflammation. A treatment that helps hands may therefore be insufficient for the spine.

Why skin, eyes and bowel change the choice

Biologic and targeted medicines act on different immune pathways. Their effects and safety differ across axial disease, peripheral joints, psoriasis, uveitis and inflammatory bowel disease. A treatment chosen for skin alone may not cover the other problems. Rheumatology may need to coordinate with dermatology, ophthalmology or gastroenterology.

Safety and response are part of treatment

Before and during treatment, the team considers infection screening, vaccination, other illnesses, pregnancy plans and medication monitoring. Persistent symptoms trigger a check of the diagnosis, inflammatory activity, adherence and other contributors. Do not stop, combine or switch medicines on the basis of a comparison chart.

Sources & further reading
  1. ASAS–EULAR axSpA management recommendations: 2022 update
  2. EULAR PsA pharmacological recommendations: 2023 update, published 2024
  3. GRAPPA treatment recommendations 2021, published 2022

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: Spondyloarthritis